18F-FET PET Differentiation of Ring-enhancing Brain Lesions
Overview
Authors
Affiliations
Unlabelled: The aim of this study was to explore the differential diagnostic value of PET using the amino acid O-(2-(18)F-fluoroethyl)-L-tyrosine ((18)F-FET) in patients with newly diagnosed solitary intracerebral lesions showing ring enhancement on contrast-enhanced MRI.
Methods: (18)F-FET PET analyses were performed on 14 consecutive patients with intracerebral ring-enhancing lesions. Eleven of the patients were additionally studied with (18)F-FDG PET. In all patients, the main differential diagnosis after MRI was a malignant lesion, in particular glioblastoma multiforme, versus a benign lesion, in particular brain abscess. A malignant tumor was suspected for lesions showing increased (18)F-FET uptake on PET images with a mean lesion-to-brain ratio of at least 1.6 ((18)F-FET PET positive). A nonneoplastic lesion was suspected in cases of minimal or absent (18)F-FET uptake, with a mean lesion-to-brain ratio of less than 1.6 ((18)F-FET PET negative). Histologic diagnosis was obtained by serial biopsies in 13 of the 14 patients. One patient refused the biopsy, but follow-up indicated an abscess because his lesion regressed under antibiotic therapy.
Results: Histology and clinical follow-up showed high-grade malignant gliomas in 5 patients and nonneoplastic lesions in 9 patients. The findings of (18)F-FET PET were positive in all 5 glioma patients and in 3 of 9 patients with nonneoplastic lesions, including 2 patients with brain abscesses and 1 patient with a demyelinating lesion. The findings of (18)F-FDG PET were positive (mean lesion-to-gray matter ratio > or = 0.7) in 4 of 4 glioma patients and 3 of 7 patients with nonneoplastic lesions.
Conclusion: Although (18)F-FET PET has been shown to be valuable for the diagnostic evaluation of brain tumors, our data indicate that, like (18)F-FDG PET, (18)F-FET PET has limited specificity in distinguishing between neoplastic and nonneoplastic ring-enhancing intracerebral lesions. Thus, histologic investigation of biopsy specimens remains mandatory to make this important differential diagnosis.
Sahu A, Mathew R, Ashtekar R, Dasgupta A, Puranik A, Mahajan A Front Nucl Med. 2024; 3:1040998.
PMID: 39355021 PMC: 11440952. DOI: 10.3389/fnume.2023.1040998.
Galldiks N, Kaufmann T, Vollmuth P, Lohmann P, Smits M, Veronesi M Neuro Oncol. 2024; 26(7):1181-1194.
PMID: 38466087 PMC: 11226881. DOI: 10.1093/neuonc/noae049.
Manzarbeitia-Arroba B, Hodolic M, Pichler R, Osipova O, Soriano-Castrejon A, Garcia-Vicente A Cancers (Basel). 2024; 16(1).
PMID: 38201621 PMC: 10778283. DOI: 10.3390/cancers16010195.
TSPO PET signal using [F]GE180 is associated with survival in recurrent gliomas.
Quach S, Holzgreve A, Kaiser L, Unterrainer M, Dekorsy F, Nelwan D Eur J Nucl Med Mol Imaging. 2022; 50(3):859-869.
PMID: 36329288 PMC: 9852133. DOI: 10.1007/s00259-022-06006-1.
Heinzel A, Dedic D, Galldiks N, Lohmann P, Stoffels G, Filss C Cancers (Basel). 2022; 14(14).
PMID: 35884396 PMC: 9319157. DOI: 10.3390/cancers14143336.